by Halia Therapeutics | Nov 29, 2023 | News & Media, Press Releases
LEHI, Utah, Nov. 29, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced positive results following the... by Halia Therapeutics | Nov 27, 2023 | Press Releases
Halia will present 3 posters with new positive data and a company showcase providing an overview of its clinical programs targeting the inflammasome LEHI, Utah, Nov. 27, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company... 
by Halia Therapeutics | Nov 20, 2023 | Press Releases
LEHI, Utah, Nov. 20, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced... 
by Halia Therapeutics | Nov 16, 2023 | Press Releases
SALT LAKE CITY, Nov. 16, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced the... 
by Halia Therapeutics | Oct 31, 2023 | Press Releases
Company announces the appointment of Dr. David Bearss, CEO of Halia Therapeutics, as a member of the Board of Directors at BioUtah LEHI, Utah, Oct. 31, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative...